Research site

Torrance, California 90509

6 studies enrolling now · 89 studies all time

What they study most

Acid Reflux Disease, Acromegaly, Active Systemic Lupus Erythematosus, Acute Coronary Syndrome, Acute Coronary Syndromes, Acute Ischaemic Stroke, Affective Psychosis, Bipolar, Anemia, Asthma, Bipolar Disorder, Bone Pain in Stage I - III Breast Cancer, Breast Cancer

Studies at this site

• An Open-label, Single-arm Study of Prophylaxis for Datopotamab Deruxtecan (Dato-DXd) -Related Stomatitis in Eligible Patients With Metastatic or Inoperable Locally Recurrent Breast Cancer or Locally Advanced or Metastatic Epidermal Growth Factor Receptor-Mutated Non-small Cell Lung Cancer. — Recruiting now
• Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen — Recruiting now
• Prevention of Recurrent C. Difficile Infection Study With AZD5148 Monoclonal Antibody — Recruiting now
• A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event — Recruiting now
• A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006) — Recruiting now
• Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS — Recruiting now
• ALXN2420 Versus Placebo in Combination With Somatostatin Analogs in Participants With Acromegaly — Stopped early
• A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma — Running, not enrolling
• A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With Clinical ASCVD or at Risk for a First ASCVD Event — Running, not enrolling
• A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer — Running, not enrolling
• A Phase IIb Study of AZD5462 in Patients With Chronic Heart Failure — Completed
• Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN) — Running, not enrolling
• AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy. — Running, not enrolling
• A Study to Evaluate the Effect of Budesonide, Glycopyrronium, Formoterol Fumarate (BGF) Metered Dose Inhaler (MDI), Budesonide and Formoterol Fumarate (BFF) MDI and Placebo MDI on Exercise Parameters in Participants With Chronic Obstructive Pulmonary Disease (COPD). — Completed
• A Study of the Long-term Safety and Tolerability of an Investigational Drug in People With Schizophrenia. — Completed
• An Extension Study to a Clinical Study That Will Continue to Evaluate the Effectiveness and Safety of SEP-363856 in People With Schizophrenia That Switch to SEP-363856 From Their From Their Current Antipsychotic Medication — Completed
• A Study to Describe the Characteristics, Health Care Interventions and Outcomes of Patients With Major Bleedings in the Presence of Factor Xa Inhibitor Treatment — Completed
• Study to Assess Efficacy and Safety of SZC for the Management of High Potassium in Patients With Symptomatic HFrEF Receiving Spironolactone — Completed
• Efficacy and Safety of MEDI6570 in Patients With a History of Myocardial Infarction — Completed
• Evaluation of Efficacy, Safety of Vandetanib in Patients With Differentiated Thyroid Cancer — Completed
• Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk — Completed
• Phase III Double-blind, Placebo-controlled Study of AZD1222 for the Prevention of COVID-19 in Adults — Completed
• Study of Verinurad in Heart Failure With Preserved Ejection Fraction — Completed
• A Study to Evaluate the Safety and Efficacy of BIIB104 in Participants With Cognitive Impairment Associated With Schizophrenia (CIAS) — Completed
• Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk Open-label Extension — Completed
• A Study to Evaluate Safety and Pharmacodynamic Efficacy of 0382 in Obese Subjects With NAFLD/NASH. — Completed
• Study of Etanercept Monotherapy vs Methotrexate Monotherapy for Maintenance of Rheumatoid Arthritis Remission — Completed
• Efficacy and Safety of Anifrolumab Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus — Completed
• Multicenter,Single-arm Study to Evaluate Efficacy, Safety, & Pharmacokinetics of Denosumab in Children w/ OI — Stopped early
• Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy — Stopped early
• LDL-C Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2 — Completed
• Effect of Dalcetrapib vs Placebo on CV Risk in a Genetically Defined Population With a Recent ACS — Completed
• An Open Label Study to Determine the Safety and Efficacy of Replacement Factor VIII Protein (Known as rFVIIIFc) in Previously Untreated Males With Severe Hemophilia A — Completed
• DETERMINE-preserved - Dapagliflozin Effect on Exercise Capacity Using a 6-minute Walk Test in Patients With Heart Failure With Preserved Ejection Fraction — Completed
• Mechanistic Evaluation of Glucose-lowering Strategies in Patients With Heart Failure — Completed
• Registrational Study With Omecamtiv Mecarbil (AMG 423) to Treat Chronic Heart Failure With Reduced Ejection Fraction — Completed
• Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE) — Stopped early
• Safety and Efficacy of Efavaleukin Alfa in Subjects With Active Rheumatoid Arthritis — Stopped early
• Evaluation of Efficacy and Safety of MEDI2070 in Patients With Active, Moderate-to-severe Crohn's Disease. — Completed
• DETERMINE-reduced - Dapagliflozin Effect on Exercise Capacity Using a 6-minute Walk Test in Patients With Heart Failure With Reduced Ejection Fraction — Completed
• Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 in Subjects With Moderate to Very Severe COPD (Ethos) — Completed
• Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure — Completed
• A Phase 3 STudy of CaPRe in LOwering Very hiGh TriglYcerides (TRILOGY 2) — Completed
• Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine — Completed
• A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus — Completed
• Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events — Completed
• Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study — Completed
• Comparing Complete Remission After Treatment With Selumetinib/Placebo in Patient With Differentiated Thyroid Cancer — Stopped early
• Abrilumab (AMG 181) in Adults With Moderate to Severe Ulcerative Colitis — Completed
• Benralizumab Efficacy in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History — Completed